Introduction
============

Pelvic fracture urethral distraction defect (PFUDD) seriously affects voiding function and the quality of life of patients ([@b1-ijmm-41-05-2733]). Urethral defects are healed by fibroblasts, but overexpression of extracellular matrix (ECM) components in the resultant scar tissue may cause a reduction or complete blockage in the urethral caliber and impairment of the flow of urine ([@b2-ijmm-41-05-2733]). Open urethroplasty of urethral strictures is performed worldwide and has become the gold standard for the treatment of urethral strictures. However, this surgery is often performed in high-volume urethral referral centers, and only surgeons with multiple years of training are able to obtain high (\~95%) success rates ([@b3-ijmm-41-05-2733]). Overall, the success rate of urethral reconstructive surgeries remains relatively low globally (short-term 79--88%, long term 42--86%) ([@b4-ijmm-41-05-2733],[@b5-ijmm-41-05-2733]). Reconstructive surgery may also result in serious morbidity at the defect location and the donor site, including infection, nerve injury and difficulties in opening the mouth ([@b2-ijmm-41-05-2733],[@b6-ijmm-41-05-2733]). To minimize side-effects and complications, micro invasive surgeries \[for example, direct visual internal urethrotomy (DVIU)\] has been used to treat posterior urethral stricture caused by PFUDD. DVIU is commonly performed in patients with urethral stricture and remains the first choice in secondary centers with limited equipment or those that lack experienced surgeons. However, high recurrence and poor long-term curative rates have been associated with this technique, and its effectiveness remains questionable among urologists ([@b7-ijmm-41-05-2733],[@b8-ijmm-41-05-2733]). Thus, there is an urgent need for novel techniques and complementary strategies to prevent fibrosis and scar formation in patients following surgery. Although the local injection and dilution of steroids and other anti-fibrosis reagents were introduced as an adjuvant treatment for DVIU, a previous systematic review and meta-analysis by our group has demonstrated that these drugs are not efficient or effective enough to decrease the recurrence rate ([@b7-ijmm-41-05-2733]).

Gene therapy has emerged as a promising treatment option for a number of diseases. Accumulating evidence indicates that microRNAs (miRNAs/miRs) are involved in multiple disease processes, including the pathogenesis of fibrosis in the skin and liver ([@b9-ijmm-41-05-2733]). Our goal is to add to the information regarding miRNA dysregulation in urethral fibrosis to broaden our understanding of the underlying pathological mechanisms and discover novel treatment targets. By conducting miRNA sequencing, temporal miRNA expression profiles were generated in urethral scar and normal urethral tissues, and potential gene targets and pathways involved in fibrosis were identified in patients suffering from PFUDD. This established miRNA profile may provide further insight into the involvement of miRNAs and their functions in the development and progression of pathological conditions.

Materials and methods
=====================

Urethral scar samples
---------------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The present study was approved by the Ethics Committee of Shanghai Sixth People\'s Hospital (Shanghai, China). Informed consent was obtained from all patients. Scar and normal urethral tissues were collected from patients with urethral stricture undergoing urethroplasty (n=5). All subjects were male with an age range of 16--59 years. Baseline patient information is summarized in [Table I](#tI-ijmm-41-05-2733){ref-type="table"}.

A total of 3 pairs of samples were used for miRNA sequencing, and 3 pairs were used for quantitative polymerase chain reaction (qPCR) verification (one patient\'s tissue was used in both miRNA sequencing and qPCR). The etiology of patients with urethral stricture was PFUDD. All the participating patients underwent primary surgery. The mean length of the stricture was 1.5 cm and the locations were all at the membranous segment of the urethra. Samples were harvested following surgery, sectioned and stored at −80°C until the process of RNA extraction.

RNA extraction and miRNA sequencing analysis
--------------------------------------------

Total RNA from each sample ([Table II](#tII-ijmm-41-05-2733){ref-type="table"}) was used to prepare the miRNA sequencing library, which included the following steps: i) 3′-adaptor ligation; ii) 5′-adaptor ligation; iii) cDNA synthesis; iv) PCR amplification; v) size selection of \~135--155 bp PCR amplified fragments (corresponding to \~15--35 nt small RNAs).

The TruSeq SR Cluster kit (cat. no. GD-402-4001; Illumina, Inc., San Diego, CA, USA) was used for cluster generation in an Illumina cBOT instrument, following the manufacturer\'s protocol. Sequencing was performed on an Illumina HiSeq^®^ 2000 instrument (Illumina, Inc.) using a TruSeq Rapid SBS kit (cat. no. FC-402-4002; Illumina, Inc.).

Following sequencing, the Solexa CHASTITY quality filtered reads were harvested as clean reads. Adaptor sequences were trimmed, and the retained reads (≥15 nt) were aligned to merged pre-miRNA databases (known pre-miRNAs from miRBase v21 ([@b10-ijmm-41-05-2733]--[@b14-ijmm-41-05-2733]) plus the newly predicted pre-miRNAs) using Novoalign software v2.07.11 \[(Novocraft Technologies Sdn Bhd, Selangor, Malaysia) maximum mismatch was 1, and low reads (total reads \<2) were discarded\]. To characterize the isomiR variability, sequences matching each miRNA precursor(s) in the mature miRNA region ±4 nt (≤1 mismatch) were accepted as mature miRNA isomiRs and grouped according to the 5-prime (5p) or 3-prime (3p) arm of the precursor hairpin. The number of mapped tags was defined as the raw expression level of the specific miRNAs. Transcripts per million values were generated based on the total number of aligned tags for normalization. The most abundant isomiR, mature miRNA (annotated in miRBase) and all isoforms of miRNA (5p or 3p) were used for miRNA expression quantification. For comparison of miRNA expression profiles between two groups (scar tissue vs. normal tissue), fold change and P-value were calculated to identify miRNAs with differentiated expression.

Reverse transcription (RT)-qPCR for the validation of miRNAs
------------------------------------------------------------

A total of 3 pairs of urethral samples were used for qPCR validation of miRNA expression. The primers used for PCR were designed with Primer Premier software (version 5.0; Premier Biosoft International, Palo Alto, CA, USA) (primer sequence details are summarized in [Table III](#tIII-ijmm-41-05-2733){ref-type="table"}). cDNA synthesis was performed on a GeneAmp PCR System 9700 (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) using a RevertAid First Strand cDNA Synthesis kit, cat. no. K1622 (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocols. qPCR was performed on a ViiA 7 Real-time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) using a PowerUp SYBR Green Master Mix, (cat. no. A25778, Thermo Fisher Scientific, Inc.). qPCR was conducted at: i) 95°C for 10 min, ii) 95°C for 15 sec and iii) 60 sec at \>60°C for 40 cycles. The fold change for each miRNA was calculated using the 2^−∆∆Cq^ method ([@b15-ijmm-41-05-2733]).

Bioinformatics analysis
-----------------------

Hierarchical clustering was performed. miRNA target prediction was performed by TargetScan, miRanda, and microcosm with DAVID Bioinformatics Resources 6.7 (<https://david-d.ncifcrf.gov/home>) ([@b16-ijmm-41-05-2733]--[@b22-ijmm-41-05-2733]). Enrichment analysis for Gene Ontology (GO) and Kyoto Encylopedia of Genes and Genomes (KEGG) pathways was performed using the topGO package in R (<https://www.bioconductor.org/packages/3.7/bioc/html/topGO.html>) ([@b20-ijmm-41-05-2733]--[@b22-ijmm-41-05-2733]).

Statistical analysis
--------------------

Comparisons between average fold changes of different miRNAs were performed using Student\'s t-tests (using the T.TEST function in Microsoft Excel; Microsoft Corporation, Redmond, WA, USA). For analysis based on miRNA sequencing only, the t-tests used a two-tailed distribution and the comparison was paired for expression in normal and scar tissues (n=3; [Table IV](#tIV-ijmm-41-05-2733){ref-type="table"}). For analysis based on both miRNA sequencing and qPCR validation ([Table V](#tV-ijmm-41-05-2733){ref-type="table"}), the t-tests used a two-tailed distribution and the comparison was paired for expression evaluated by the two methods \[miRNA sequencing and qPCR, n=7 (for upregulated miRNAs) and n=15 (for downregulated miRNAs)\].

Histological evaluation
-----------------------

Freshly harvested scar and normal tissue were fixed in 4% paraformaldehyde at 4°C for over 24 h, dehydrated and embedded in paraffin following standard protocols by Servicebio, Inc. (Wuhan Servicebio Technology Co., Ltd., Wuhan, Hubei, China). The samples were stored and sectioned at room temperature; 4 µm sections were incubated in a 65°C oven for 2 h and de-paraffinized by washing with xylene and a descending alcohol gradient (100, 100, 85 and 75% for immunohistochemistry staining; 100, 95, 90, 80 and 70% for Masson trichrome staining) prior to staining.

Immunohistochemistry and Masson trichrome staining were performed using mouse-anti-human monoclonal transforming growth factor (TGF)-β1 antibodies (1:200, cat. no. GB11179, Servicebio, Inc., Wuhan Servicebio Technology Co., Ltd.) and Masson trichrome (cat. no. PT003; Shanghai Bogoo Biotechnology. Co., Ltd., Shanghai, China) following the manufacturer\'s protocols. Secondary antibody staining involved the DAKO REAL EnVision Detection System, Peroxidase/DAB, Rabbit/Mouse (cat. no. K5007; Agilent Technologies, Inc., Santa Clara, CA, USA) and a Masson staining kit (cat. no. G1006; Servicebio, Inc., Wuhan Servicebio Technology Co., Ltd.) according to the manufacturer\'s protocols.

Results
=======

miRNA expression results based on sequencing data
-------------------------------------------------

All sequencing samples were evaluated for RNA quality ([Table II](#tII-ijmm-41-05-2733){ref-type="table"}) and an miRNA expression profile was generated to identify differentially expressed miRNAs in scar tissues of patients with urethral stricture. Out of the 1,620 human miRNAs that were sequenced, 55 miRNAs were upregulated (fold change \>2) and 39 were downregulated (fold change \<0.5).

A total of 26 differentially expressed miRNAs were identified, with 5 upregulated and 21 downregulated (P\<0.05; [Fig. 1](#f1-ijmm-41-05-2733){ref-type="fig"}). The fold changes and P-values were summarized in [Table IV](#tIV-ijmm-41-05-2733){ref-type="table"}.

Valitation of miRNAs with qPCR
------------------------------

qPCR was performed for miRNAs with significant changes based on the miRNA sequencing data ([Fig. 2](#f2-ijmm-41-05-2733){ref-type="fig"}). miRNA upregulation identified by miRNA sequencing was validated by qPCR (P=0.51; paired t-test comparisons; n=7), while miRNA downregulation identified by miRNA sequencing was quite different from the data generated by qPCR (P\<0.01; paired t-test comparisons; n=15; [Table V](#tV-ijmm-41-05-2733){ref-type="table"}). Among these, hsa-miR-129-5p was overexpressed in scar tissue compared with normal tissue, although the difference was not significant. Hsa-miR-223-3p and hsa-miR-20a-5p expression was slightly decreased in scar tissues compared with normal tissues. Hsa-miR-26a-5p, hsa-miR-92a-3p, hsa-miR-29c-3p and hsa-miR-125b-5p demonstrated slight changes in expression, but showed opposite regulation patterns as validated by qPCR. Given the fact that sample size was small and the materials harvested were limited in the present study, it was not possible to generate certain conclusions or rule out the possibility of sample variety in this case. Further functional validation will be required to confirm the involvement of these candidate miRNAs in fibrosis, scar formation and PFUDD.

GO and KEGG pathway analysis
----------------------------

The predicted biological processes, molecular function, cellular components and KEGG pathways associated with miR-129-5p, miR-9-5p, miR-6720-3p, miR-363-3p and miR-135a-5p were analyzed ([Figs. 3](#f3-ijmm-41-05-2733){ref-type="fig"}[](#f4-ijmm-41-05-2733){ref-type="fig"}[](#f5-ijmm-41-05-2733){ref-type="fig"}[](#f6-ijmm-41-05-2733){ref-type="fig"}--[7](#f7-ijmm-41-05-2733){ref-type="fig"}). As expected, these miRNAs were predicted to be most frequently involved in \'regulation of transcription\' and \'RNA metabolic process\'. miR-129-5p, miR-9-5p and miR-135a-5p were predicted to function in ion binding, while miR-6720-3p in both ion binding and DNA binding. miR-363-3p was the only miRNA predicted to molecularly regulate transcription and protein kinase activity. Cellular component analysis suggested that miR-129-5p, miR-9-5p and miR-135a-5p were associated with \'plasma membrane\', miR-6720-3p in \'membrane-enclosed lumen\', and miR-363-3p in \'non-membrane bounded organelles\'. KEGG pathway analysis indicated that four miRNAs (miR-129-5p, miR-9-5p, miR-6720-3p and miR-135a-5p) may regulate pathways in cancer.

TGF-β and collagen are upregulated in urethral scar tissue, but not normal tissue
---------------------------------------------------------------------------------

TGF-β signaling has been confirmed to be involved in fibrosis. To investigate whether TGF-β signaling was affected in scar tissues, immunostaining for TGF-β1 protein was performed. As expected, TGF-β1 expression was increased in urethral scar tissues compared with normal tissues from the same patient ([Fig. 8A and B](#f8-ijmm-41-05-2733){ref-type="fig"}). Similarly, dense collagen distribution and irregular fiber alignment was observed in urethral scar tissues, but not in normal tissue ([Fig. 8C and D](#f8-ijmm-41-05-2733){ref-type="fig"}).

Discussion
==========

miR-129-5p potentially regulates 17 genes that are directly associated with TGF-β pathway members ([Fig. 9](#f9-ijmm-41-05-2733){ref-type="fig"}), indicating that it may serve an important function in fibrosis through the regulation of TGF-β signalling. miR-129-5p has previously been reported to be significantly downregulated following TGF-β1 treatment in kidney proximal tubular cells ([@b23-ijmm-41-05-2733]). In addition, miR-129-5p is downregulated in fibroblasts in systemic sclerosis (or scleroderma, an acquired disorder that typically results in fibrosis of the skin and internal organs), and upregulated miR-129-5p (induced by interleukin-17A) suppresses α1 collagen protein expression levels in normal fibroblasts ([@b24-ijmm-41-05-2733]). The present study suggested that miR-129-5p is upregulated in scar tissues from patients with PFUDD compared with normal tissues, and further analysis is required to assess whether the downstream targets in TGF-β pathway are functionally affected, and whether miR-129-5p regulation is driving the fibrosis or results from fibrosis as a feedback effect.

Besides its fibrosis-associated functions, miR-129-5p has also been reported as a regulator of epithelial-to-mesenchymal transition (EMT) in epithelial cells ([@b23-ijmm-41-05-2733]). miR-129-5p is significantly downregulated in various types of cancer, including lung cancer, breast cancer, gastric cancer and glioblastoma, and over-expression of miR-129-5R suppresses cell viability, proliferation, migration and invasion, while promoting cell apoptosis ([@b25-ijmm-41-05-2733]--[@b28-ijmm-41-05-2733]). miR-129-5p has also been demonstrated to negatively regulate a specific circular RNA (hsa-circ-0005986) and Notch1, and downregulated hsa-circ-0005986 may promote the proliferation of hepatocellular carcinoma cells ([@b29-ijmm-41-05-2733]). Investigation of miR-129-5p and its potential targets through TGF-β-independent regulations in PFUDD may prove interesting.

miR-9-5p expression is increased in lung tissues from patients with idiopathic pulmonary fibrosis and in the lungs of mice with bleomycin-induced lung fibrosis ([@b30-ijmm-41-05-2733]). Overexpression of miR-9-5p inhibits TGF-β1-induced lung fibrosis, and inhibition of miR-9-5p amplifies the transformation of human lung fibroblasts into myofibroblasts ([@b30-ijmm-41-05-2733]). Overexpression of hsa-miR-9-5p may prevent fibrogenesis in skin fibrosis, mediated by suppressing TGF-β signaling, and inhibition of miR-9-5p results in increased expression of fibrosis markers ([@b31-ijmm-41-05-2733]). Hsa-miR-9-5p is upregulated in TGF-β1-treated human dermal fibroblasts ([@b31-ijmm-41-05-2733]). Overexpression of miR-9-5p significantly delays TGF-β-dependent transformation of dermal fibroblasts, decreases the expression of the ECM proteins collagen, type I, α1 and fibronectin, the amount of secreted collagen proteins and the expression of the archetypal myofibroblast marker α-smooth muscle actin ([@b31-ijmm-41-05-2733]). In contrast to this, specific inhibition of miR-9-5p resulted in enhanced presence of fibrosis markers ([@b31-ijmm-41-05-2733]). The upregulation of hsa-miR-9-5p observed in the present study may have been an induced auto-suppression effect of fibrosis, and an analysis with larger cohort and further validation may be helpful to understand its function during the process.

Little is known about the involvement of miR-363-3p, miR-135a-5p or miR-6720-3p in fibrosis regulation. The majority of the research concerning these three miRNAs focuses on their function in carcinogenesis. For example, miR-363-3p is downregulated in tissues from patients with non-small cell lung cancer and gallbladder cancer, and in cluster of differentiation 133-positive cancer stem-like cells isolated from patients with larynx cancer ([@b32-ijmm-41-05-2733]--[@b34-ijmm-41-05-2733]). miR-363-3p significantly inhibits cell growth *in vitro* and *in vivo* in lung cancer cells, and induces cell cycle arrest and promote cell apoptosis, potentially through proliferating cell nuclear antigen and its ability to inhibit the activation of the mechanistic target of rapamycin and extracellular signal-regulated kinase (ERK) signaling pathways ([@b33-ijmm-41-05-2733],[@b35-ijmm-41-05-2733]). In patients with prostate cancer, miR-363-3p expression was decreased in serum and its level was negatively correlated with risk of recurrence and progression, suggesting that it may serve as a potential diagnostic and prognostic biomarker for prostate cancer ([@b36-ijmm-41-05-2733]). Similarly, in colorectal cancer, miR-363-3p was downregulated in the tissues of patients, and its expression was negatively associated with metastatic status ([@b37-ijmm-41-05-2733]). miR-363-3p inhibits colorectal cancer cell migration and invasion and inhibits EMT, potentially through targeting SRY-box 4 ([@b37-ijmm-41-05-2733]). Inhibition of miR-363-3p induces cell cycle arrest and suppresses apoptosis in gallbladder cancer cells, potentially by targeting and competing with the long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 in the regulation of the MCL1, BCL2 family apoptosis regulator gene ([@b34-ijmm-41-05-2733]).

miR-135a-5p is upregulated in liver biopsy samples from patients with chronic hepatitis C or hepatitis C virus (HCV), but is not induced by anti-viral response to HCV infection ([@b38-ijmm-41-05-2733]). By targeting and inducing silencing of protein tyrosine phosphatase receptor δ, a tumor suppressor, miR-135a-5p may potentially drive HCV-associated hepatocarcinogenesis ([@b38-ijmm-41-05-2733]).

miR-6720 has been reported to be upregulated in hepatocellular carcinoma cells following treatment with alternariol, a mycotoxin ([@b39-ijmm-41-05-2733]). However, not much evidence is available concerning its functions in TGF-β regulated signaling transduction.

As a shared potential target of hsa-miR-129-5p, hsa-miR-135a-5p and hsa-miR-363-3p, the G protein-coupled receptor kinase 5 (GRK5) gene encodes a member of the guanine nucleotide-binding protein-coupled receptor kinase subfamily of the Ser/Thr protein kinase family. GRK5 mRNA and protein expression is increased in the lungs of patients with cystic fibrosis compared with normal donors ([@b40-ijmm-41-05-2733]). GRK5 has been identified as a regulator of aldosterone-mineralocorticoid receptor/angiotensin II type 1 receptor-mediated cardiomyocyte hypertrophy ([@b41-ijmm-41-05-2733]). Molecular analysis has revealed that overexpression of N-terminal GRK5 inhibits apoptosis and fibrosis, which are major pathogenic phenotypes that accompany cardiac hypertrophy, through nuclear factor-κB signaling ([@b42-ijmm-41-05-2733]). Knockout of GRK5 inhibits cardiac fibrosis induced by metoprolol, a β~1~-adrenergic receptor-selective blocker, and this regulation is dependent on β-arrestins but independent of G-protein signaling ([@b43-ijmm-41-05-2733]).

TGF-β1 and collagen were overexpressed in scar tissues in the present study ([Fig. 8](#f8-ijmm-41-05-2733){ref-type="fig"}), indicating that the TGF-β pathway was upregulated. TGF-β1 is a key regulatory molecule in the pathogenesis of fibrosis, and is frequently upregulated during this process ([@b44-ijmm-41-05-2733],[@b45-ijmm-41-05-2733]). Inhibition of TGF-β1 or its receptors, including TGF-β receptor 1, may reverse the unilateral ureteral occlusion-induced increase of fibrotic biomarkers, including TGF-β1, collagens and fibronectin, at the mRNA level ([@b44-ijmm-41-05-2733]). The increase of TGF-β1 and collagen may result in excessive fibrosis in scar tissue, and it is unclear how the regulatory miRNAs and genes that regulate TGF-β signaling are involved in this process. Potential crosstalk between miRNAs and their target genes are listed, together with the associated signaling molecules involved in TGF-β1 regulated fibrosis ([Fig. 9](#f9-ijmm-41-05-2733){ref-type="fig"}).

It is worth noting that mitogen-activated protein kinase 1, proliferation and apoptosis adaptor protein 15, transducer of ERBB2, 1 and valosin containing protein gene products are predicted to interact with one or more TGF-β pathway proteins, as presented in [Fig. 9](#f9-ijmm-41-05-2733){ref-type="fig"}. Among the associated TGF-β pathway genes, SMAD family member 3, mitogen-activated protein kinase 7 and ERK1/2 are the most frequently targeted candidates for potential interactions. Given the fact that crosstalk between SMADs and the ERK signaling pathway is essential in fibrosis ([@b46-ijmm-41-05-2733]), further functional analysis focusing on those \'hotspots\' in larger cohorts may prove interesting.

In conclusion, the present study sequenced the urethral scar and normal tissue from patients with urethral stricture. miRNA sequencing indicated significantly altered expression of hsa-miR-129-5p, hsa-miR-135a-5p, hsa-miR-363-3p, hsa-miR-6720-3p and hsa-miR-9-5p. Bioinformatics analysis revealed that these miRNAs and their potential target genes are associated with fibrosis in other diseases. These data may provide miRNA targets for future precision treatments for urethral stricture.
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![Hierarchical clustering of 26 miRs with significant changes in expression (fold change \>2 or \<0.5; P\<0.05) in the urethral scar and normal urethral tissue groups. Red indicates high expression, and green indicates low expression. miR, microRNA.](IJMM-41-05-2733-g00){#f1-ijmm-41-05-2733}

![Validation of sequencing data by real time quantitative polymerase chain reaction. Triplicate assays were performed for each RNA sample. Red indicates high expression, and green indicates low expression. miR, microRNA.](IJMM-41-05-2733-g01){#f2-ijmm-41-05-2733}

![Biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes pathways of microRNA-129-5p. MAPK, mitogen-activated protein kinase.](IJMM-41-05-2733-g02){#f3-ijmm-41-05-2733}

![Biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes pathways of microRNA-9-5p. MAPK, mitogen-activated protein kinase.](IJMM-41-05-2733-g03){#f4-ijmm-41-05-2733}

![Biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes pathways of microRNA-6720-3p.](IJMM-41-05-2733-g04){#f5-ijmm-41-05-2733}

![Biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes pathways of microRNA-363-3p.](IJMM-41-05-2733-g05){#f6-ijmm-41-05-2733}

![Biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes pathways of microRNA-135a-5p. MAPK, mitogen-activated protein kinase; Jak-STAT, Janus kinase-signal transducer and activator of transcription.](IJMM-41-05-2733-g06){#f7-ijmm-41-05-2733}

![TGF-β1 and collagen are overexpressed in urethral scar tissues compared with normal tissues. Anti-TGF-β1 (brown) immunostating in (A) urethral scar tissue or (B) normal urethral tissue. Masson trichrome staining in (C) urethral scar tissue or in (D) normal urethral tissue. Collagen (blue), muscle fiber (red), cytoplasm (light red/pink) were labeled with their corresponding colors. Scale bar, 100 µm. TGF-β1, transforming growth factor-β1.](IJMM-41-05-2733-g07){#f8-ijmm-41-05-2733}

![Crosstalk between miRNAs and target genes associated with TGF-β1 regulated fibrosis. MiRNAs and genes that are \'hotspots\' (interacting with multiple targets or predicted interacting partners) are in bold. miRNAs/miRs, microRNAs; TGF-β1, transforming growth factor-β1.](IJMM-41-05-2733-g08){#f9-ijmm-41-05-2733}

###### 

Baseline patient characteristics.

  Patient number   Age   Sex    Health status
  ---------------- ----- ------ ---------------
  1                59    Male   PFUDD
  2                50    Male   PFUDD
  3                16    Male   PFUDD
  4                43    Male   PFUDD
  5                44    Male   PFUDD

PFUDD, pelvic fracture urethral distraction defects.

###### 

RNA quality control characteristics for microRNA sequencing samples.

  Sample ID[a](#tfn2-ijmm-41-05-2733){ref-type="table-fn"}   OD260/280 ratio   OD260/230 ratio   Conc. (ng/µl)   Volume (µl)   Quantity (ng)   QC
  ---------------------------------------------------------- ----------------- ----------------- --------------- ------------- --------------- ------
  Normal 1                                                   1.87              2.40              316.68          30            9500.40         Pass
  Scar 1                                                     1.85              2.38              282.52          40            11300.80        Pass
  Normal 2                                                   1.86              2.41              182.11          20            3642.20         Pass
  Scar 2                                                     1.88              2.39              237.14          40            9485.60         Pass
  Normal 3                                                   1.81              2.40              144.77          10            1447.70         Pass
  Scar 3                                                     1.88              2.30              267.73          40            10709.20        Pass

In Sample ID, 1, 2 and 3 indicate specific patients (for example, 1 for Patient 1). OD, optical density; QC, quality control.

###### 

MicroRNA primers for quantitative real-time PCR.

  Primer name                Primer sequence (5′-3′)
  -------------------------- ----------------------------------------------
  U6-S                       CTCGCTTCGGCAGCACA
  U6-A                       AACGCTTCACGAATTTGCGT
  general control primer-A   TGGTGTCGTGGAGTCG
  hsa-miR-129-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGCAAGCCC
  hsa-miR-129-5p-S           ACACTCCAGCTGGGCTTTTTGCGGTCTGG
  hsa-miR-9-5p-RT            CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCATACAG
  hsa-miR-9-5p-S             ACACTCCAGCTGGGTCTTTGGTTATCTAGCT
  hsa-miR-9-3p-RT            CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACTTTCGG
  hsa-miR-9-3p-S             ACACTCCAGCTGGGATAAAGCTAGATAACC
  hsa-miR-183-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGTGAATT
  hsa-miR-183-5p-S           ACACTCCAGCTGGGTATGGCACTGGTAGAA
  hsa-miR-6720-3p-RT         CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCTACCAG
  hsa-miR-6720-3p-S          ACACTCCAGCTGGGCGCGCCTGCAGGAACT
  hsa-miR-96-5p-RT           CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGCAAAAA
  hsa-miR-96-5p-S            ACACTCCAGCTGGGTTTGGCACTAGCACATT
  hsa-miR-486-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCTCGGGGC
  hsa-miR-486-5p-S           ACACTCCAGCTGGGTCCTGTACTGAGCTGC
  hsa-miR-363-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTACAGATG
  hsa-miR-363-3p-S           ACACTCCAGCTGGGAATTGCACGGTATCCA
  hsa-miR-135a-5p-RT         CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCACATAG
  hsa-miR-135a-5p-S          ACACTCCAGCTGGGTATGGCTTTTTATTCCT
  hsa-miR-374a-3p-RT         CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAATTACAA
  hsa-miR-374a-3p-S          ACACTCCAGCTGGGCTTATCAGATTGTATT
  hsa-miR-374b-3p-RT         CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAATGATAA
  hsa-miR-374b-3p-S          ACACTCCAGCTGGGCTTAGCAGGTTGTATT
  hsa-miR-941-RT             CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGCACATGT
  hsa-miR-941-S              ACACTCCAGCTGGGCACCCGGCTGTGTGCAC
  hsa-miR-3158-3p-RT         CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGTCCTGCA
  hsa-miR-3158-3p-S          ACACTCCAGCTGGGAAGGGCTTCCTCTCTG
  hsa-miR-29c-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTAACCGAT
  hsa-miR-29c-3p-S           ACACTCCAGCTGGGTAGCACCATTTGAAAT
  hsa-miR-10a-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTATTCCCC
  hsa-miR-10a-3p-S           ACACTCCAGCTGGGCAAATTCGTATCTAGG
  hsa-miR-182-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGTGTGAG
  hsa-miR-182-5p-S           ACACTCCAGCTGGGTTTGGCAATGGTAGAACT
  hsa-miR-106a-5p-RT         CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCTACCTGC
  hsa-miR-106a-5p-S          ACACTCCAGCTGGGAAAAGTGCTTACAGTGC
  hsa-miR-4284-RT            CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGATGGGGTG
  hsa-miR-4284-S             ACACTCCAGCTGGGGGGCTCACATCA
  has-mir192-5p-RT           CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGGCTGTCA
  has-mir192-5p-S            ACACTCCAGCTGGGCTGACCTATGAATTG
  hsa-miR-26a-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGCCTATC
  hsa-miR-26a-5p-S           ACACTCCAGCTGGGTTCAAGTAATCCAGGA
  hsa-miR-223-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTGGGGTAT
  hsa-miR-223-3p-S           ACACTCCAGCTGGGTGTCAGTTTGTCAAAT
  hsa-miR-92a-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACAGGCCG
  hsa-miR-92a-3p-S           ACACTCCAGCTGGGTATTGCACTTGTCCCG
  hsa-miR-29b-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAACACTGA
  hsa-miR-29b-3p-S           ACACTCCAGCTGGGTAGCACCATTTGAAATC
  hsa-miR-125b-5p            CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCACAAGT
  hsa-miR-125b-5p            ACACTCCAGCTGGGTCCCTGAGACCCTAAC
  hsa-miR-194-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCCACATG
  hsa-miR-194-5p-S           ACACTCCAGCTGGGTGTAACAGCAACTCCA
  hsa-miR-20a-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCTACCTGC
  hsa-miR-20a-5p-S           ACACTCCAGCTGGGTAAAGTGCTTATAGTGC
  hsa-miR-128-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAAAGAGAC
  hsa-miR-128-3p-S           ACACTCCAGCTGGGTCACAGTGAACCGGT
  hsa-miR-654-5p-S           ACACTCCAGCTGGGTGGTGGGCCGCAGAAC
  hsa-miR-654-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGCACATGT
  hsa-miR-31-3p-S            ACACTCCAGCTGGGTGCTATGCCAACATAT
  hsa-miR-31-3p-RT           CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGATGGCAAT
  hsa-miR-329-3p-S           ACACTCCAGCTGGGAACACACCTGGTTAAC
  hsa-miR-329-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAAAGAGGT
  hsa-let-7b-3p-S            ACACTCCAGCTGGGCTATACAACCTACTGC
  hsa-let-7b-3p-RT           CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGGAAGGC
  hsa-miR-433-3p-S           ACACTCCAGCTGGGATCATGATGGGCTCCT
  hsa-miR-433-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACACCGAG
  hsa-miR-379-3p-S           ACACTCCAGCTGGGTATGTAACATGGTCCA
  hsa-miR-379-3p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGTTAGTG
  hsa-miR-744-5p-S           ACACTCCAGCTGGGTGCGGGGCTAGGGCTA
  hsa-miR-744-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTGCTGTTA
  hsa-miR-29c-5p-S           ACACTCCAGCTGGGTGACCGATTTCTCCTG
  hsa-miR-29c-5p-RT          CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGAACACCA

###### 

miRs with significantly different expression, as identified by miR sequencing.

  A, Upregulated genes                                 
  ------------------------ --------------------------- --------------------------------------------------------
  hsa-miR-129-5p           3.75                        0.026
  hsa-miR-9-5p             2.08                        0.003
  hsa-miR-374a-3p          1.92                        0.039
  hsa-miR-374b-3p          1.42                        0.008
  hsa-miR-128-3p           1.19                        0.014
                                                       
  B, Downregulated genes                               
                                                       
  miR                      Fold change (scar/normal)   P-value[a](#tfn3-ijmm-41-05-2733){ref-type="table-fn"}
                                                       
  hsa-miR-26a-5p           0.91                        0.004
  hsa-miR-941              0.90                        0.019
  hsa-miR-223-3p           0.83                        0.043
  hsa-miR-3158-3p          0.78                        0.025
  hsa-miR-20a-5p           0.72                        0.035
  hsa-miR-92a-3p           0.70                        0.039
  hsa-miR-29c-3p           0.69                        0.002
  hsa-miR-194-5p           0.67                        0.000
  hsa-miR-125b-5p          0.67                        0.005
  hsa-miR-29b-3p           0.64                        0.008
  hsa-miR-192-5p           0.63                        0.041
  hsa-miR-10a-3p           0.62                        0.023
  hsa-miR-182-5p           0.51                        0.016
  hsa-miR-106a-5p          0.46                        0.038
  hsa-miR-183-5p           0.45                        0.013
  hsa-miR-6720-3p          0.38                        0.038
  hsa-miR-96-5p            0.33                        0.037
  hsa-miR-486-5p           0.27                        0.035
  hsa-miR-363-3p           0.26                        0.014
  hsa-miR-135a-5p          0.19                        0.004
  hsa-miR-4284             0.17                        0.038

Scar vs. normal, t-test, paired. miR, microRNA.

###### 

Comparison between miR sequencing and qPCR sequencing.

  miR               Average change by miR sequencing (scar/normal)   Average change by qPCR (scar/normal)
  ----------------- ------------------------------------------------ --------------------------------------
  has-miR-129-5p    3.75                                             2.13
  hsa-miR-654-5p    2.06                                             1.57
  hsa-miR-31-3p     1.55                                             1.08
  hsa-miR-433-3p    1.42                                             2.36
  hsa-miR-329-3p    1.32                                             2.46
  hsa-let-7b-3p     1.17                                             2.71
  hsa-miR-379-3p    1.17                                             2.23
  hsa-miR-26a-5p    0.91                                             1.13
  hsa-miR-744-5p    0.84                                             2.52
  hsa-miR-223-3p    0.83                                             0.54
  hsa-miR-20a-5p    0.72                                             0.98
  hsa-miR-92a-3p    0.70                                             1.12
  hsa-miR-29c-3p    0.69                                             1.74
  hsa-miR-125b-5p   0.67                                             1.70
  hsa-miR-29c-5p    0.67                                             3.01
  hsa-miR-192-5p    0.63                                             2.35
  hsa-miR-106a-5p   0.46                                             1.19
  hsa-miR-183-5p    0.45                                             2.22
  hsa-miR-96-5p     0.33                                             1.77
  hsa-miR-486-5p    0.27                                             1.84
  hsa-miR-4284      0.17                                             2.03

miR, microRNA; qPCR, quantitative polymerase chain reaction.

[^1]: Contributed equally
